Search

everythinglearnresearchcommunity

for

Search:↓

GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.

Concerns about the effectiveness of DHT inhibitors like finasteride and minoxidil due to potential polymorph issues. Experts suggest these concerns are largely unfounded, especially compared to rare cases like ritonavir.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

RU58841 is discussed as a potential hair loss treatment. Minoxidil and finasteride are also mentioned as common treatments.

Redensyl was discussed for hair loss treatment, but one user reported no effect. Minoxidil, finasteride, and RU58841 were also mentioned.

The conclusion of the conversation is that the user, djamezz, has experienced significant regrowth and improved density in their hairline by using treatments such as RU (RU58841), dut (dutasteride), and Inkey's Caffeine Scalp treatment. They are satisfied with their progress and do not plan to cut off their hair.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.

The conversation discusses concerns about using hair fibers while microneedling, specifically the potential for clogging pores. It is suggested that microneedling should not cause bleeding.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks upcoming Fluridil group buys.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

The user has been using oral minoxidil and finasteride but continues to experience hair thinning. They are considering adding RU58841 or dutasteride to their regimen for better results.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

User discusses topical liposomal finasteride for hair loss, hoping to avoid breast growth side effect. Conversation includes using minoxidil, fluridil, and dermarolling, and mentions minimal systemic absorption of liposomal finasteride.

A 2-week journey with Pyri, which is producing positive effects on hair texture and reduced shedding; Minoxidil and derma needling are being used as treatments.

Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.

Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.

The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.

A user is considering mixing fast-drying minoxidil with Kirkland minoxidil to reduce greasiness and drying time. They also use liquid minoxidil to apply RU58841 powder.

Microneedling with 5% minoxidil improves hair growth for hair loss patients. Best protocol: 1.5mm dermaroller weekly for 12 weeks or 0.6mm dermapen every 2 weeks for 12 weeks, skipping topicals for 24 hours.

A user's experience with Pyrilutamide, a topical treatment for hair loss that they used in combination with other treatments such as Minoxidil and Finasteride. The user experienced impressive results in a short amount of time.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

A user's success in hair regrowth after taking oral and topical medications, such as minoxidil and dutasteride, and using microneedling. Other users shared their experiences and advice with treatments used to reverse hair loss.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.